Comparative Pharmacology
Head-to-head clinical analysis: AGRYLIN versus CLOLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGRYLIN versus CLOLAR.
AGRYLIN vs CLOLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
None Documented
None Documented
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with CrCl <60 mL/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent